Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Elin BarnekowDepartment of Clinical Science and Education, Karolinska Institutet, 11883 Stockholm, Sweden.ORCID 0000-0002-4960-664X
Wen LiuDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.
Mikael Andersson FrankoDepartment of Clinical Science and Education, Karolinska Institutet, 11883 Stockholm, Sweden.ORCID 0000-0002-9837-4486
Anna von WachenfeldtDepartment of Clinical Science and Education, Karolinska Institutet, 11883 Stockholm, Sweden.
Camilla WendtDepartment of Clinical Science and Education, Karolinska Institutet, 11883 Stockholm, Sweden.
Emma ThamDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.ORCID 0000-0001-6079-164X
Miriam MintsDepartment of Women's and Children's Health, Karolinska University Hospital, 17177 Stockholm, Sweden.
Tracy A O'MaraCancer Research Program, QIMR Berghofer, Brisbane, QLD 4006, Australia.ORCID 0000-0002-5436-3232
Per HallDepartment of Oncology, Södersjukhuset, 11883 Stockholm, Sweden.
Sara MargolinDepartment of Clinical Science and Education, Karolinska Institutet, 11883 Stockholm, Sweden.
Annika LindblomDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.ORCID 0000-0001-7675-7569
Funding
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPSR01CA058598 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GOODMAN, MARC T · 1993 to 2012
$4.6M
The Mitochondrial Genome and Ovarian Cancer RiskR01CA149429 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PHELAN, CATHERINE · 2010 to 2015
$3.1M
Cancer UK Grant A16563Cancer UK Grant C1287CIHR MOP-86727European Community's Seventh Framework Programme 223175Genome Canada Grant GPH-129344Märit and Hans Rausing´s initiative against Breast cancerNational Health and Medical Research Council 1031333National Health and Medical Research Council 1109286National Health and Medical Research Council ID1111246National Health and Medical Research Council ID1173170National Institute of Health U19 CA148065NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA149429NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112Ovarian Cancer Research Fund 268201200008IStockholm County Council 500395Swedish Cancer Society 18-0700Swedish Research Council 2019-01441The Cancer Research Funds of Radiumhemmet 191203US National Institutes of Health CA1X01HG007491-01US National Institutes of Health R01-CA058598US National Institutes of Health R01-CA149429US National Institutes of Health U19-CA148112
6 · The paper itself
Abstract
Breast and endometrial cancer are prevalent and share both hormonal and environmental risk factors. This study aimed to identify shared germline genetic risk loci for these cancers. In total, 1116 endometrial cancer cases, 3200 breast cancer cases, and 5021 healthy controls were included in a merged sliding window haplotype genome-wide association study (GWAS). This analysis employed a logistic regression model in PLINK v1.07. The results from this merged analysis were compared with previous individual analyses of the same samples. The analysis identified three loci that influenced both the risk of breast and endometrial cancer: 8p21.1 (OR 2.1;
Indexed as
Breast NeoplasmsEndometrial NeoplasmsGenetic LociGenetic Predisposition to DiseaseGenome-Wide Association StudyHaplotypesCase-Control StudiesChromosomes, Human, Pair 16Chromosomes, Human, Pair 17FemaleHumansMiddle AgedPolymorphism, Single NucleotideRisk FactorsSwedenbreast cancerendometrial cancergenetic risk lociGWAShaplotype
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Novel Shared Heritable Candidate Risk Loci of Breast and Endometrial Cancer-A Swedish Haplotype Genome-Wide Association Study. · full record | Socratic